Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by biorunon Jan 29, 2024 5:56pm
93 Views
Post# 35851501

RE:RE:RE:New Press Release - Sirona Biochem Announces Loan

RE:RE:RE:New Press Release - Sirona Biochem Announces LoanAnyone who lends this kind of money has to know they have a pretty much 100% chance of getting paid back. 

And he is making 12% plus another 450,000 bonus shares. The risk payment (interest) doesn't match the reward because it is him in the privileged information seat. He can also demand the money be paid back on priority notice in the event something is about to sour overall..

Again, I would argue "follow the motivation of the money". He is essentially augmenting his salary but if anyone here really knows what is around the corner it is him.

So I would argue, let's let greed and capitalism play out here. I would be willing to bet there is plenty in the bush here, otherwise he would have done this before and lent this kind of money on any of the previous rounds.



<< Previous
Bullboard Posts
Next >>